3-甲基-6-(1-哌嗪基)哒嗪 | 219635-87-7

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二嗪烷类
• 中文名称: 3-甲基-6-(1-哌嗪基)哒嗪
• 中文别名: 2H-吡喃-2-酮,四氢-4-羟基-5-甲基-6-(1-甲基乙基)-,(4S,5S,6R)-
• 英文名称: 3-Methyl-6-piperazin-1-ylpyridazine
• CAS: 219635-87-7
• 化学式: C₉H₁₄N₄
• 分子量: 178.237
• InChiKey: VJRHTFKXROTZLL-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0
• 重原子数：
  13
• 可旋转键数：
  1
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.56
• 拓扑面积：
  41
• 氢给体数：
  1
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  4-异丙基苯异氰酸酯 、 3-甲基-6-(1-哌嗪基)哒嗪 以 四氢呋喃 为溶剂， 反应 2.0h， 生成 4-(6-Methyl-pyridazin-3-yl)-piperazine-1-carboxylic acid (4-isopropyl-phenyl)-amide
  参考文献：
  名称：

  Synthesis and evaluation of pyridazinylpiperazines as vanilloid receptor 1 antagonists

  摘要：

  A structurally biased chemical library of pyridazinylpiperazine analogs was prepared in an effort to improve the pharmaceutical and pharmacological profile of the lead compound N-(4-tertiarybutylphenyl)-4-(3-chloropyridin-2-yl)tetrahydropyrazine-1(2H)-carboxamide (BCTC). The library was evaluated for VR1 antagonist activity in capsaicin-induced (CAP) and pH 5.5-induced (pH) FLIPR assays in a human VR1-expressing HEK293 cell line. The most potent VR1 antagonists were found to have IC50 values in the range of 9-200nM with improved pharmaceutical and pharmacological profiles versus the lead BCTC. These compounds represent possible second-generation BCTC analogs. (C) 2004 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2004.09.010
• 作为产物：
  描述：

  哌嗪 、 3-氯-6-甲基哒嗪 在 三乙胺 作用下， 以 二甲基亚砜 为溶剂， 反应 6.0h， 生成 3-甲基-6-(1-哌嗪基)哒嗪
  参考文献：
  名称：

  Synthesis and evaluation of pyridazinylpiperazines as vanilloid receptor 1 antagonists

  摘要：

  A structurally biased chemical library of pyridazinylpiperazine analogs was prepared in an effort to improve the pharmaceutical and pharmacological profile of the lead compound N-(4-tertiarybutylphenyl)-4-(3-chloropyridin-2-yl)tetrahydropyrazine-1(2H)-carboxamide (BCTC). The library was evaluated for VR1 antagonist activity in capsaicin-induced (CAP) and pH 5.5-induced (pH) FLIPR assays in a human VR1-expressing HEK293 cell line. The most potent VR1 antagonists were found to have IC50 values in the range of 9-200nM with improved pharmaceutical and pharmacological profiles versus the lead BCTC. These compounds represent possible second-generation BCTC analogs. (C) 2004 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2004.09.010

文献信息

• Aryl carbamate derivatives, preperation and use thereof
  申请人：——

  公开号：US20040058933A1

  公开（公告）日：2004-03-25

  The present invention relates to novel compounds, the preparation and use, particularly therapeutic, thereof. More specifically, it relates to compounds derived from aryl carbamates, the preparation and use thereof, particularly in the field of human and animal health. The compounds according to the invention are preferably 5-HT 4 serotoninergic receptor ligands and can therefore be used in the therapeutic or prophylactic treatment of any disorder involving a 5-HT 4 receptor. The invention also relates to pharmaceutical compositions comprising such compounds, the preparation and use thereof and treatment methods using said compounds.

  本发明涉及新化合物，其制备和使用，特别是在治疗方面。更具体地说，它涉及从芳基氨基甲酸酯衍生的化合物，其制备和使用，特别是在人类和动物健康领域。根据本发明的化合物首选是5-HT4受体的血清素受体配体，因此可以在治疗或预防涉及5-HT4受体的任何疾病的治疗中使用。本发明还涉及包含此类化合物的药物组合物，其制备和使用以及使用该化合物的治疗方法。
• NOVEL 9-SUBSTITUTED-5-CARBOXY-OXADIAZINO-QUINOLONE DERIVATIVES, THEIR PREPARATION AND THEIR APPLICATION AS ANTI-BACTERIALS
  申请人：Ropp Sandrine

  公开号：US20100009980A1

  公开（公告）日：2010-01-14

  A subject of the invention is the compounds of formula (I): wherein R 1 , R 2 , R 3 , R′ 3 , R 4 , R′ 4 , R 5 , R 6 and R 7 are as described in the application, in the form of enantiomers or mixtures, as well as their salts with acids and bases, their preparation and their application as anti-bacterials, in both human and veterinary medicine.

  本发明涉及以下式（I）的化合物：其中R1、R2、R3、R′3、R4、R′4、R5、R6和R7如申请中所述，以对映体或混合物的形式存在，以及它们与酸和碱的盐，它们的制备以及它们作为抗菌剂在人类和兽医医学中的应用。
• ANTIVIRAL AGENTS
  申请人：Watson Keith

  公开号：US20070149530A1

  公开（公告）日：2007-06-28

  This invention relates to compounds of formula I their salts, and pharmaceutically acceptable derivatives thereof, pharmaceutical compositions comprising these compounds and their use in the treatment of picornavirus infections in mammals, as well as novel intermediates useful in the preparation of the compounds of formula I.

  本发明涉及公式I化合物及其盐和药学上可接受的衍生物，包括这些化合物的制剂和它们在哺乳动物的小肠病毒感染治疗中的使用，以及在制备公式I化合物中有用的新型中间体。
• CHEMICAL COMPOUNDS
  申请人：Jones Lyn Howard

  公开号：US20090264425A1

  公开（公告）日：2009-10-22

  This invention relates to biaryl ether derivatives of formula (I) wherein R 1 , R 3 , R 4 , X, W, Y and m are defined in the description, and to compositions containing them and the uses of such derivatives. The compounds of the present invention bind to the enzyme reverse transcriptase and are modulators, especially inhibitors thereof.

  本发明涉及公式（I）的二芳基醚衍生物，其中R1、R3、R4、X、W、Y和m在说明中定义，并涉及含有它们的组合物以及这些衍生物的用途。本发明的化合物与酶逆转录酶结合，并且是其调节剂，特别是抑制剂。
• PYRIDO[3,4-d]PYRIMIDINE DERIVATIVE AND PHARMACEUTICALLY ACCEPTABLE SALT THEREOF
  申请人：Teijin Pharma Limited

  公开号：EP3305785A1

  公开（公告）日：2018-04-11

  The purpose of the present invention is to provide a compound having an excellent CDK4/6 inhibiting activity. The present invention is a compound represented by general formula (I) or a pharmaceutically acceptable salt thereof.

  本发明的目的是提供一种具有优异 CDK4/6 抑制活性的化合物。本发明是通式（I）代表的化合物或其药学上可接受的盐。